Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind mitapivat vs placebo in transfusion-dependent thalassemia
2021-000212-34Phase 3Active
- Sponsor
- Agios Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Thalassaemia comparing Mitapivat with Placebo (2 arms). Primary endpoint: Transfusion reduction response (TRR). Started Jun 2021; status: active.
02
Drugs
mitapivat
03
Conditions
Thalassaemia
Beyond the preview
Go deeper on 2021-000212-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000212-34.